TipRanks
Bristol-Myers Squibb (DE:BRM)
XETRA:BRM
Germany Market
BRM
Bristol-Myers Squibb
RESEARCH TOOLSreports

Bristol-Myers Squibb (BRM) Stock News & Sentiment

20 Followers
BMY Terminates Early Leukemia Trial, Trimming One Risky Bet From Its Oncology Pipeline
Premium
Company Announcements
BMY Terminates Early Leukemia Trial, Trimming One Risky Bet From Its Oncology Pipeline
2d ago
BMY
Bristol-Myers Squibb: Pipeline Risks Balance Core Strengths, Justifying Hold Rating and Unchanged $60 Price Target
Premium
Ratings
Bristol-Myers Squibb: Pipeline Risks Balance Core Strengths, Justifying Hold Rating and Unchanged $60 Price Target
3d ago
BMY
BMY Expands Real-World Cancer Data With New AUGTYRO Study in Korea
Premium
Company Announcements
BMY Expands Real-World Cancer Data With New AUGTYRO Study in Korea
3d ago
BMY
Bristol-Myers Squibb’s Real‑World Luspatercept Study Wraps Up, Setting the Stage for Next Growth Moves
Premium
Company Announcements
Bristol-Myers Squibb’s Real‑World Luspatercept Study Wraps Up, Setting the Stage for Next Growth Moves
3d ago
BMY
The Week That Was, The Week Ahead: Macro and Markets, September 27
Premium
Market News
The Week That Was, The Week Ahead: Macro and Markets, September 27
7d ago
O
CM
Bristol-Myers Squibb: Pipeline Uncertainties and Limited IPF Upside Lead Flynn to Reiterate Sell Rating and Maintain $40 Price Target
Premium
Ratings
Bristol-Myers Squibb: Pipeline Uncertainties and Limited IPF Upside Lead Flynn to Reiterate Sell Rating and Maintain $40 Price Target
9d ago
BMY
BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline
Premium
Company Announcements
BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline
9d ago
BMY
More DE:BRM News >

BRM News on the Web

Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?
The Motley Fool
Bullish
FDA Approves Bristol Myers Squibb's Camzyos for Pediatric Obstructive Hypertrophic ...
GuruFocus News
Bullish
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool
Bearish
Bristol Myers Squibb (BMY) Faces Liver Injury Concerns in Admilparant Trials Amid Dividend Stability
GuruFocus News
Neutral
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool
Bullish
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.
The Motley Fool
Neutral
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
Insider Monkey
Neutral
Why Women-Run Companies Deserve a Place in Your Portfolio
Zacks
Neutral

News Score - Last 7 Days

Positive
DE:BRM
Sector Average
Media Buzz
This Week26 articles
Weekly Average19 articles
News Sentiment
This Week75%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:BRM’s Media Buzz Sentiment?
26 articles about DE:BRM were published this week. In an average week, 19 articles are published.
    What is DE:BRM’s weekly average amount of articles?
    In an average week, 19 articles about DE:BRM are published.
      What is DE:BRM’s News Sentiment?
      75% of articles about DE:BRM were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        RHHBYRoche Holding
        BAYRYBayer
        SNYSanofi
        CICigna
        TFXTeleflex
        Showing the stocks with the most bullish news sentiment over the past week